Age and frailty in COVID-19 vaccine development

Melissa K. Andrew, Janet E. McElhaney

Producción científica: Contribución a una revistaComentario/debaterevisión exhaustiva

42 Citas (Scopus)
Idioma originalEnglish
Páginas (desde-hasta)1942-1944
Número de páginas3
PublicaciónThe Lancet
Volumen396
N.º10267
DOI
EstadoPublished - dic. 19 2020

Nota bibliográfica

Funding Information:
MKA reports grants from the Canadian Frailty Network, Sanofi, Pfizer, and GlaxoSmithKline, personal fees from Pfizer for advisory board membership, and personal fees from Sanofi for advisory board membership and consulting about severe outcomes of influenza in older adults. MKA reports agreement to future payments for serving as a member of the data safety monitoring board for a COVID-19 vaccine trial funded by ImmunoVaccine Technologies. JEM reports personal fees from RestorBio and Sanofi for advisory board membership, GlaxoSmithKline and Merck for data safety monitoring board memberships related to vaccine development outside of COVID-19, and personal fees for serving on the Scientific Advisory Board for an influenza vaccine trial sponsored by Medicago.

ASJC Scopus Subject Areas

  • General Medicine

PubMed: MeSH publication types

  • Journal Article
  • Comment

Citar esto